Literature DB >> 6972305

Anti-idiotypic immunity and autoimmunity. I. In vitro and in vivo effects of anti-idiotypic antibodies to spontaneously occurring autoantibodies to rat thyroglobulin.

M Zanetti, P E Bigazzi.   

Abstract

The effects of anti-receptor (anti-idiotypic) immunity on autoimmune responses have been investigated in Buffalo (BUF) rats with autoimmune thyroiditis. As compared to other animal models of autoimmune disease, BUF rat thyroiditis has the following advantages: it occurs in an inbred strain, arises spontaneously (i.e. without the experimental administration of autoantigens and adjuvants) and is characterized by production of autoantibodies to only one autoantigen, thyroglobulin. Finally, its pathogenesis is mediated by autoantibodies to rat thyroglobulin, and therefore this model is particularly suitable to study the effects of anti-idiotypic reactions on those autoimmune disorders whose damage is caused by humoral immunity. The experiments reported in the present study show that first, heterologous anti-idiotypic antibodies to autoantibodies against rat thyroglobulin have been produced and characterized. It has then been demonstrated that such anti-idiotypic antibodies are capable of inhibiting the in vitro binding between thyroglobulin and thyroglobulin autoantibodies obtained from BUF rats. It has also been shown that repeated injections of anti-idiotypic antibodies into sublethally X-irradiated BUF rats with autoimmune thyroiditis were followed by a significant change in the levels of circulating autoantibodies to rat thyroglobulin. These results provide evidence that in spite of the complexity of autoantigens and the heterogeneity of autoimmune responses, established autoimmune diseases may be controlled by sequential immunosuppression and anti-idiotypic immunity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972305     DOI: 10.1002/eji.1830110306

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Curtailment of autoimmunity following parabiosis with a normal partner.

Authors:  P McCullagh
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

Review 2.  Idiotypes and autoimmunity.

Authors:  D K Male
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

3.  Experimental autoimmune uveoretinitis: idiotypic regulation and disease suppression.

Authors:  Y De Kozak; M Mirshahi
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

4.  IVIG treatment for VZV-related acute inflammatory polyneuropathy in a child.

Authors:  Danilo Buonsenso; Benedetta Focarelli; Piero Valentini; Roberta Onesimo
Journal:  BMJ Case Rep       Date:  2012-07-19

5.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.

Authors:  G Dietrich; M D Kazatchkine
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

6.  Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome.

Authors:  A Hietaharju; M Korpela; J Ilonen; H Frey
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

7.  Anti-idiotypic antibody production in hepatitis B vaccine recipients.

Authors:  K Kobayashi; Y Ueno; H Suzuki; M Miura; R Nagatomi; M Ishii; T Toyota
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

Review 8.  Idiotypes and autoimmunity.

Authors:  I M Roitt; D K Male; A Cooke; P M Lydyard
Journal:  Springer Semin Immunopathol       Date:  1983

9.  The assessment of anti-idiopathic antibodies as effective immunoregulatory probes in vivo.

Authors:  J C Olson; C R Wagner; G A Leslie
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

10.  Antiidiotypic antibodies to sperm in sera of fertile women that neutralize antisperm antibodies.

Authors:  R K Naz; K Ahmad; A C Menge
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.